Literature DB >> 22192841

Weight change in people with type 2 diabetes: secular trends and the impact of alternative antihyperglycaemic drugs.

C Ll Morgan1, S Jenkins-Jones, M Evans, A H Barnett, C D Poole, C J Currie.   

Abstract

AIM: This study aimed to describe the pattern of weight change in people with type 2 diabetes (T2DM) over time and when using alternative treatment regimens.
METHODS: Data were from routine clinical practice in the UK. The weight trend was determined for each year from 1995 to 2010 for both prevalent and incident cases. Baseline weight was compared to absolute (mean Δ) and relative weights (% Δ) at 6, 12 and 24 months.
RESULTS: Mean, standardized weight in prevalent cases increased from 83.4 to 92.1 kg for males and from 73.5 to 79.9 kg for females between 1995 and 2010 (p < 0.0001). For incident cases, the respective figures were 86.7 to 93.6 kg for males and 76.0 to 80.7 kg for females (p < 0.001). Between baseline and 6, 12 and 24 months, there were significant changes in weight for the majority of the treatment regimens selected for analysis. The largest weight increase at 12 months was for the patients who were prescribed a combination therapy with insulin and a thiazolidinedione, with a median increase of 4.1 kg (95% CI -0.60 to 8.0, p < 0.001). The largest weight decrease at 12 months was for the patients who were prescribed a combination therapy of metformin and exenatide, with a median decrease of -7.0 kg (95% CI -12.0 to -2.0, p < 0.001).
CONCLUSIONS: There was a continual increase in body weight in people with T2DM over time, and considerable differences in the impact on weight using alternative treatment regimens. At the same time, glycaemic control remained relatively unchanged.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22192841     DOI: 10.1111/j.1463-1326.2011.01552.x

Source DB:  PubMed          Journal:  Diabetes Obes Metab        ISSN: 1462-8902            Impact factor:   6.577


  17 in total

Review 1.  Metformin and ageing: improving ageing outcomes beyond glycaemic control.

Authors:  Willy Marcos Valencia; Ana Palacio; Leonardo Tamariz; Hermes Florez
Journal:  Diabetologia       Date:  2017-08-02       Impact factor: 10.122

2.  Weight change after initiation of oral hypoglycemic monotherapy for diabetes predicts 5-year mortality: An observational study.

Authors:  Beverly M Kocarnik; Kathryn P Moore; Nicholas L Smith; Edward J Boyko
Journal:  Diabetes Res Clin Pract       Date:  2016-12-05       Impact factor: 5.602

Review 3.  The journey of metformin from glycaemic control to mTOR inhibition and the suppression of tumour growth.

Authors:  Sam Amin; Andrew Lux; Finbar O'Callaghan
Journal:  Br J Clin Pharmacol       Date:  2018-11-08       Impact factor: 4.335

4.  Low body mass index and old age are useful in predicting the hemoglobin A1c-lowering effect of switching from sitagliptin to dulaglutide in Japanese patients with type 2 diabetes mellitus: a single-center, open-label, single-arm, pilot study.

Authors:  Tomoyuki Iwasaki; Takaomi Kessoku; Takuma Higurashi; Masataka Taguri; Masato Yoneda
Journal:  Diabetol Int       Date:  2018-02-02

5.  Efficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: A 52-week open-label study.

Authors:  Nobuya Inagaki; Kazuoki Kondo; Toru Yoshinari; Hideki Kuki
Journal:  J Diabetes Investig       Date:  2014-08-25       Impact factor: 4.232

6.  Baseline low-density lipoprotein cholesterol predicts the hemoglobin A1c-lowering effect of dapagliflozin in Japanese patients with type 2 diabetes mellitus.

Authors:  Tomoyuki Iwasaki; Masato Yoneda
Journal:  Diabetol Int       Date:  2015-05-31

7.  Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.

Authors:  Hans-Ulrich Häring; Ludwig Merker; Elke Seewaldt-Becker; Marc Weimer; Thomas Meinicke; Hans J Woerle; Uli C Broedl
Journal:  Diabetes Care       Date:  2013-08-20       Impact factor: 19.112

8.  Association of Weight Loss and Medication Adherence Among Adults With Type 2 Diabetes Mellitus: SHIELD (Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes).

Authors:  Susan Grandy; Kathleen M Fox; Elise Hardy
Journal:  Curr Ther Res Clin Exp       Date:  2013-12

9.  Patterns of weight change after the diagnosis of type 2 diabetes in Scotland and their relationship with glycaemic control, mortality and cardiovascular outcomes: a retrospective cohort study.

Authors:  Lorna S Aucott; Sam Philip; Alison Avenell; Ebenezer Afolabi; Naveed Sattar; Sarah Wild
Journal:  BMJ Open       Date:  2016-07-26       Impact factor: 2.692

10.  Addition of sulphonylurea to metformin does not relevantly change body weight: a prospective observational cohort study (ZODIAC-39).

Authors:  Dennis Schrijnders; Raiza Wever; Nanne Kleefstra; Sebastiaan T Houweling; Kornelis J J van Hateren; Geertruida H de Bock; Henk J G Bilo; Klaas H Groenier; Gijs W D Landman
Journal:  Diabetes Obes Metab       Date:  2016-07-13       Impact factor: 6.577

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.